Evaluation of ICP-B208 in Patients With Advanced Solid Tumors

An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials

To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors

Inclusion Criteria:

1. 18 years old to 75 years old;
2. Unresectable locally advanced or metastatic gastrointestinal tumors or other advanced solid tumors that have failed previous systemic treatment and have been confirmed by histopathology or cytology;
3. The ECOG physical fitness score is 0 to 1 point.
4. There is at least one measurable lesion;
5. The organ function level must meet the prescribed standards;
6. Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug.
7. Voluntarily enroll in the group and sign the informed consent form, and follow the trial treatment protocol and visit plan.

Exclusion Criteria:

1. Other active malignant tumors occurred within 3 years before the first administration of the study drug;
2. Received the anti-tumor treatment defined by the protocol within the time range before the first administration of the study drug specified in the protocol;
3. Trial participants with unstable primary CNS tumors or CNS metastases;
4. Uncontrollable or significant major cardiovascular diseases;
5. Severe or uncontrollable systemic diseases; Or any unstable systemic disease;
6. Active infection as defined in the plan;
7. Have a history of severe allergic reactions to active pharmaceutical ingredients, non-active components in drugs or antibody drugs;
8. Those who are known to have a history of alcohol abuse or drug abuse;
9. Other circumstances that the researcher deems unsuitable for participation in this study.